| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
313.95(M) |
| Last
Volume: |
1,560,200 |
Avg
Vol: |
2,306,261 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
92,653 |
92,653 |
204,995 |
510,803 |
| Total Sell Value |
$124,554 |
$124,554 |
$194,453 |
$1,231,647 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
4 |
13 |
34 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-04-06 |
4 |
AS |
$91.69 |
$10,131,745 |
D/D |
(110,500) |
67,394 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-04-06 |
4 |
OE |
$7.21 |
$1,005,505 |
D/D |
110,500 |
177,894 |
|
- |
|
| Chess Robert |
Director |
– • – |
2018-04-06 |
4 |
AS |
$92.14 |
$2,303,600 |
D/D |
(25,000) |
274,223 |
|
- |
|
| Chess Robert |
Director |
– • – |
2018-04-06 |
4 |
OE |
$5.14 |
$219,700 |
D/D |
25,000 |
289,223 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2018-04-06 |
4 |
AS |
$92.22 |
$2,766,600 |
D/D |
(30,000) |
130,333 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2018-04-06 |
4 |
OE |
$14.26 |
$427,800 |
D/D |
30,000 |
160,333 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-04-05 |
4 |
AS |
$101.75 |
$2,035,000 |
D/D |
(20,000) |
80,261 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-04-05 |
4 |
OE |
$7.21 |
$144,200 |
D/D |
20,000 |
100,261 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2018-04-05 |
4 |
AS |
$101.74 |
$3,052,200 |
D/D |
(30,000) |
27,450 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2018-04-05 |
4 |
OE |
$9.24 |
$277,200 |
D/D |
30,000 |
57,450 |
|
- |
|
| Kuebler Christopher A |
Director |
– • – |
2018-03-07 |
4 |
S |
$97.41 |
$3,643,134 |
D/D |
(37,400) |
40,500 |
|
- |
|
| Kuebler Christopher A |
Director |
– • – |
2018-03-07 |
4 |
OE |
$5.14 |
$233,236 |
D/D |
37,400 |
77,900 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2018-03-07 |
4 |
S |
$100.45 |
$10,059,465 |
D/D |
(100,144) |
167,513 |
|
- |
|
| Kuebler Christopher A |
Director |
– • – |
2018-03-06 |
4 |
S |
$100.30 |
$260,780 |
D/D |
(2,600) |
40,500 |
|
- |
|
| Kuebler Christopher A |
Director |
– • – |
2018-03-06 |
4 |
OE |
$5.14 |
$13,364 |
D/D |
2,600 |
43,100 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2018-03-06 |
4 |
S |
$98.29 |
$11,794,800 |
D/D |
(120,000) |
267,657 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-02-16 |
4 |
S |
$82.94 |
$1,060,637 |
D/D |
(12,788) |
237,147 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2018-02-16 |
4 |
S |
$82.94 |
$404,664 |
D/D |
(4,879) |
387,657 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2018-02-16 |
4 |
S |
$82.94 |
$288,382 |
D/D |
(3,477) |
99,739 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-02-16 |
4 |
S |
$82.94 |
$238,453 |
D/D |
(2,875) |
80,261 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-02-16 |
4 |
S |
$82.94 |
$201,212 |
D/D |
(2,426) |
67,394 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2018-02-16 |
4 |
S |
$82.94 |
$211,082 |
D/D |
(2,545) |
68,857 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2018-01-31 |
4 |
OE |
$11.34 |
$1,360,800 |
D/D |
120,000 |
392,536 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-01-22 |
4 |
AS |
$75.82 |
$6,318,308 |
D/D |
(83,333) |
249,935 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-01-22 |
4 |
OE |
$11.34 |
$944,996 |
D/D |
83,333 |
333,268 |
|
- |
|
913 Records found
|
|
Page 16 of 37 |
|
|
